| Wong, Rebecca |
| Completed | 4 | 71 | US | Sugammadex, Placebo | Emory University, National Center for Advancing Translational Sciences (NCATS), Georgia Clinical & Translational Science Alliance (CTSA) | Neuromuscular Blockade | 08/24 | 08/24 | | |
NCT04084548: Perioperative Lidocaine and Ketamine in Abdominal Surgery |
|
|
| Active, not recruiting | 3 | 420 | US | Lidocaine and ketamine, Lidocaine, Ketamine, Placebo | The Cleveland Clinic | Postoperative Pain | 12/24 | 12/24 | | |
TALES, NCT03011684: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial |
|
|
| Recruiting | 3 | 144 | US | Tamoxifen, Letrozole | University of California, San Francisco | Infertility | 01/25 | 01/25 | | |
| Active, not recruiting | 3 | 788 | US | Modified natural cycle, Programmed cycle | JHSPH Center for Clinical Trials | Pregnancy Related, Pre-Eclampsia | 04/25 | 08/25 | | |
| Recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide | RayzeBio, Inc., RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 12/25 | 07/28 | | |
NCT01761929: 5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases |
|
|
| Completed | 2 | 138 | Canada | Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance | University Health Network, Toronto, Princess Margaret Hospital, Canada | Solid Tumors With Oligometastatic Spread | 02/23 | 02/23 | | |
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
|
|
| Recruiting | 2 | 270 | Europe, Canada, US, RoW | Buloxibutid, C21, Placebo | Vicore Pharma AB, Population Services International | Idiopathic Pulmonary Fibrosis (IPF) | 02/27 | 03/27 | | |
NCT04467515: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer |
|
|
| Terminated | 1/2 | 13 | Canada, US | CAM-H2 | Precirix | Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment | 12/23 | 12/23 | | |
| Recruiting | N/A | 180 | Canada | Surgery Alone, Combined Surgery and Radiation therapy | University Health Network, Toronto | Cancer, Metastatic Malignant Neoplasm to Femur, Risk of Fracture | 02/25 | 02/25 | | |
S-C-PATHY, NCT06390657: Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors |
|
|
| Not yet recruiting | N/A | 20 | Europe | Planning CT, MRI | EBG MedAustron GmbH, The Princess Margaret Cancer Foundation | Cancer | 12/25 | 12/25 | | |
MDS & PRRT, NCT06510868: Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy |
|
|
| Not yet recruiting | N/A | 45 | Canada | Peptide receptor radionuclide therapy (PRRT), Blood collection | University Health Network, Toronto | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 04/28 | 06/29 | | |
NCT01279408: Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC) |
|
|
| Active, not recruiting | N/A | 46 | Canada | None: Questionnaire Study | University Health Network, Toronto | Non-small Cell Lung Carcinoma | 11/28 | 11/28 | | |
| Veitch, Elizabeth |
| Active, not recruiting | 3 | 597 | Europe, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 07/25 | 07/25 | | |
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
|
|
| Recruiting | 2 | 270 | Europe, Canada, US, RoW | Buloxibutid, C21, Placebo | Vicore Pharma AB, Population Services International | Idiopathic Pulmonary Fibrosis (IPF) | 02/27 | 03/27 | | |
| Bondue, Benjamin |
| Active, not recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo | Savara Inc., Savara ApS, | Autoimmune Pulmonary Alveolar Proteinosis | 11/23 | 11/24 | | |
| Active, not recruiting | 3 | 597 | Europe, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 07/25 | 07/25 | | |
FAPIPET, NCT06189820: Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases |
|
|
| Recruiting | 2 | 70 | Europe | FAPI PET/CT | Erasme University Hospital | Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP | 03/27 | 03/27 | | |
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
|
|
| Recruiting | 2 | 270 | Europe, Canada, US, RoW | Buloxibutid, C21, Placebo | Vicore Pharma AB, Population Services International | Idiopathic Pulmonary Fibrosis (IPF) | 02/27 | 03/27 | | |
